DRUG COSTS
Out of control—or delivering value?
Read about five key regulatory and economic issues facing life sciences companies in 2026.
Medicare Advantage (MA) and Part D insurers are citing significant financial headwinds in earnings calls and the press. Statutory financial statements provide insights into emerging trends through year-end 2024.
Maximum Fair Price (MFP) Issue Brief 2
Amid the development of new cell and gene therapies, we present some strategies that states have used to control costs and risk among their MCOs.
Biosimilars recently have made significant strides toward greater acceptance and utilization since their first U.S. approval in 2015, although challenges persist.
This report provides insights into pharmacy cost and utilization trends based on our analysis of the Milliman Consolidated Health Cost Guidelines Sources Database.
Five reasons why RFPs with PBMs should be a regular practice to help control Rx costs.
The Inflation Reduction Act’s higher standards for retiree prescription drug plans may require plan sponsors to enrich benefits in 2025 for creditable coverage.
As a new federal law, effective in 2024, removes a cap on manufacturers' drug rebate amounts, we explore the implications for state Medicaid programs.
LWith increased consumer and regulatory scrutiny on drug prices, stakeholders in the pharmacy supply chain are exploring drug pricing alternatives.
The Medicare Part D program is on the verge of massive change due to passage of the Inflation Reduction Act.
What do Part D plan sponsors need to consider when rebates cease to exist?
Prescription Drug Pricing Reduction Act proposes major changes to Part D
